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SCIENCE FOR JUDGES II 
INTRODUCTION 
Margaret A. Berger* 
This issue of the Journal of Law and Policy contains a second 
installment of articles about science-related questions that arise in 
the litigation context. As previously explained, these essays are 
expanded and edited versions of presentations made to federal and 
state judges at programs funded by the Common Benefit Trust 
established in the Silicone Breast Implant Products Liability 
Litigation.1 These conferences are held at Brooklyn Law School 
under the auspices of its Center for Health Law and Policy, in 
collaboration with the Federal Judicial Center, the National Center 
for State Courts, and the National Academies of Science=s Panel on 
Science, Technology and Law. Science for Judges II focused on 
two principal topics: (1) the practice of epidemiology and its role 
in judicial proceedings; and (2) the production of science through 
the regulatory process of administrative agencies. 
Epidemiology has played a significant role in toxic tort actions 
in proving causation, often the most crucial issue in dispute. A 
failure to prove causation means a victory for the defense. Many 
courts consider epidemiologic evidence the “gold standard” of 
proof, and some judges go so far as to hold that a plaintiff cannot 
prevail in proving causation in the absence of confirmatory 
epidemiologic studies.2 The three papers on epidemiology by 
                                                          
 * Suzanne J. and Norman Miles Professor of Law, Brooklyn Law School. 
Professor Berger is the Director of the Science for Judges Program. 
1 See Margaret A. Berger, Introduction, Science for Judges, 12 J. L. & 
POL’Y 1 (2003). 
2 See, e.g., Wade-Greaux v. Whitehall Labs., Inc., 874 F. Supp. 1441, 1480 
(D.V.I. 1994). 
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extremely well-credentialed scientists should therefore be of 
considerable interest to anyone concerned with toxic tort litigation. 
The first, by Professor John Concato of the Yale University School 
of Medicine, provides an overview of different research designs 
that epidemiologists employ in conducting studies. The second, by 
Professors Joseph Lau and John Ioannidis of the Tufts-New 
England Medical Center, discusses how and when multiple 
epidemiologic studies can be combined. The final paper by 
Professor James Robins of the Harvard School of Public Health 
expresses skepticism about hinging compensation in toxic tort 
actions on proof of causation derived from epidemiologic data. 
The second set of papers deals with science produced by 
administrative agencies. An introductory comment by Professor 
Richard Merrill of the University of Virginia Law School explains 
that both the Federal Drug Administration (FDA) and the 
Environmental Protection Agency (EPA)—which are responsible 
for regulating the great majority of products that become the 
subject of toxic tort litigation—require scientific studies and make 
scientific assessments in the course of their work. The science that 
is produced may subsequently become relevant in court 
proceedings when, for instance, a plaintiff claims that taking a drug 
approved by the FDA caused adverse health effects. Papers by Dr. 
Michael Friedman, formerly with the FDA, and Robert Sussman, 
Esq., formerly with the EPA, discuss the respective roles of these 
agencies in creating scientific information. Professor Wendy 
Wagner of the University of Texas Law School writes of a 
relatively new phenomenon: the importation into regulatory 
decision-making of a new approach that has its roots in the 
Daubert3 test used by federal courts in determining the 
                                                          
The notion that one can accurately extrapolate from animal data to 
humans to prove causation without supportive positive epidemiologic 
studies is scientifically invalid because it is inconsistent with several 
universally accepted and tested scientific principles. 
Id. 
3 In Daubert v. Merrrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), 
the first of the Supreme Court=s recent cases on the admissibility of expert 
testimony, the Court imposed an obligation on federal district judges to screen 
scientific opinions proffered by an expert to ensure  scientific reliability before 
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admissibility of expert testimony. In the final paper, Professor 
Sheila Jasanoff of the John F. Kennedy School of Government at 
Harvard University and Dogan Parese provide a comparative 
perspective by contrasting the policies that drive the treatment of 
asbestos claims in the United States with those that lead Great 
Britain and the Netherlands to manage the compensation of 
asbestos victims through administrative rather than judicial 
processing. 
These brief descriptions of the papers contained in this issue of 
the Journal provide a glimpse of the complexity and importance of 
the scientific and policy issues that courts encounter when 
handling toxic tort litigation. It is the hope of the organizers of the 
Science for Judges programs that these papers will prove useful to 
judges and lawyers who deal with the daunting questions that arise 
at the intersection of science and the law. 
 
                                                          
allowing the expert to testify. 
